Our results indicated that levothyroxine supplementation blunted the onset of experimental T1DM using the RIP‐B7.1 model, which recapitulates the β‐cell‐specific autoimmune attack that suffer patients with T1DM (Lopez‐Noriega et al., 2017). Here, CD80 is linked to type 1 diabetes mellitus.